TrialJournal for immunotherapy of cancer2022

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Patrick Schöffski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.